Plasmodium falciparum nucleic acid and protein synthesis machinery

The Plasmodium falciparum nucleic acid and protein synthesis machinery encompasses the essential biochemical pathways and structural components required for the parasite's replication and survival (PMID: 22437465). This includes enzymes involved in folate metabolism and nucleotide biosynthesis, such as dihydrofolate reductase and dihydropteroate synthase, as well as the transcriptional and translational apparatus located in the nucleus, cytoplasm, and apicoplast (UniProt). Drugs targeting these systems, such as antifolates (e.g., pyrimethamine) and various antibiotics (e.g., doxycycline), disrupt the parasite's ability to produce DNA, RNA, and essential proteins, leading to growth arrest or death (PubMed). Because the parasite's machinery often differs significantly from human counterparts—particularly in the apicoplast, which contains prokaryotic-like ribosomes—these pathways offer high selectivity for antimalarial therapy (NIH). However, the rapid emergence of drug resistance through point mutations in target enzymes remains a significant challenge in clinical management (StatPearls). Furthermore, many protein synthesis inhibitors exhibit a 'delayed death' phenotype, where the parasite only dies in the second life cycle after exposure, necessitating combination therapies for acute illness (PubMed). The machinery also includes unique aminoacyl-tRNA synthetases that are being explored as novel drug targets to overcome existing resistance (Nature Communications).

Other names

P. falciparum translation and transcription machineryMalarial protein synthesis apparatusPlasmodium falciparum biosynthetic machinery

Inhibition of essential biosynthetic processes including DNA replication, RNA transcription, and protein translation through the targeting of enzymes like dihydrofolate reductase or ribosomal subunits.